First eligible participant screened - phase 1 IRX-616a study
Filed with ASX · · 2 pages · English
Nexalis Therapeutics Limited on 6ix
Earlier from Nexalis Therapeutics
- Preliminary Final Report
- Dec25 Quarterly Activities Report
- Dec25 Appendix 4C Cash Flow Report
- IRX Overview Presentation - SRX-25 and Nexalis
- $12.6m Facility to Drive SRX-25 Development
Later from Nexalis Therapeutics
- First patient dosed in IRX-616a Phase 1 trial
- Significant Milestone - First Patient Screened IRX-211 Ph2
- Mar26 Appendix 4C Cash Flow Report
- Suspension from Quotation
- Binding Letter of Intent to replace existing $53m facility
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics